Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users
- 488 Downloads
Ecstasy (MDMA) is a psychostimulant drug which is increasingly associated with psychobiological dysfunction. While some recent studies suggest acute changes in neuroendocrine function, less is known about long-term changes in HPA functionality in recreational users.
The current study is the first to explore the effects of ecstasy–polydrug use on psychological distress and basal functioning of the HPA axis through assessing the secretion of cortisol across the diurnal period.
Seventy-six participants (21 nonusers, 29 light ecstasy–polydrug users, 26 heavy ecstasy–polydrug users) completed a substance use inventory and measures of psychological distress at baseline, then two consecutive days of cortisol sampling (on awakening, 30 min post awakening, between 1400 and 1600 hours and pre bedtime). On day 2, participants also attended the laboratory to complete a 20-min multitasking stressor.
Both user groups exhibited significantly greater levels of anxiety and depression than nonusers. On day 1, all participants exhibited a typical cortisol profile, though light users had significantly elevated levels pre-bed. On day 2, heavy users demonstrated elevated levels upon awakening and all ecstasy–polydrug users demonstrated elevated pre-bed levels compared to non-users. Significant between group differences were also observed in afternoon cortisol levels and in overall cortisol secretion across the day.
The increases in anxiety and depression are in line with previous observations in recreational ecstasy–polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.
KeywordsMDMA Ecstasy Cortisol HPA axis Cortisol awakening response
The authors wish to thank Anthea Wilde for conducting the cortisol assays.
- Cole JC, Sumnall HR, Grob CS (2002) Sorted: Ecstasy facts and fiction. The Psychologist 15(9):464–467Google Scholar
- Department of Health (2010) United Kingdom drug situation: annual report to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)Google Scholar
- Elder GJ, Wetherell MA, Barclay NL, Ellis JG (2013) The cortisol awakening response—Applications and implications for sleep medicine. Sleep Med Rev. doi:10.1016/j.smrv.2013.05.001Google Scholar
- Gerra G, Bassignana S, Zaimovic A, Moi G, Bussandri M, Caccavari R, Brambilla F, Molina E (2003) Hypothalamic–pituitary–adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine (‘ecstasy’)use history: correlation with dopamine receptor sensitivity. Psychiat Res 120:115–124CrossRefGoogle Scholar
- Gerra G, Zaimovic A, Chittolini B, Giucastro G, Folli F, Maestri D, Tessoni A, Avanzini P, Caccavari R, Bernasconi S, Brambilla F (1998) Neurotransmitter-hormonal responses to psychological stress in peripubertal subjects; relationship to aggressive behavior. Life Sci 62:617–625PubMedCrossRefGoogle Scholar
- Kraemer HC, Giese‐Davis J, Yutsis MBA, O’Hara R, Neri EBS, Gallagher‐Thompson D, Taylor CB, Spiegel D (2006) Design decisions in order to optimise reliability of daytime diurnal slopes in an older population. Am J Geriatr Psychiatry 14:325–333Google Scholar
- NIH National Institute on Drug Abuse (2012) Monitoring the futureGoogle Scholar
- Parrott AC (2009) Cortisol and 3,4‐Methylenedioxymethamphetamine: Neurohormonal aspects of bioenergetic stress in ecstasy users. Neuropsychobiology 60:148–158Google Scholar
- Wolff K, Aitchison KJ (2013) Reply to ‘MDMA can increase cortical levels by 800% in dance clubbers’ Parrott, et al. J Psychopharmacol 27:115Google Scholar
- Wolff K, Tsapakis EM, Pariante CM, Kerwin RW, Forsling ML, Aitchison KJ (2012) Pharmacogenetic studies of changes in cortisol on ecstasy (MDMA) consumption. J Psychopharmacol 26(3):419–428Google Scholar